{"id":463251,"date":"2010-03-23T16:29:25","date_gmt":"2010-03-23T20:29:25","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=69925"},"modified":"2010-03-23T16:29:25","modified_gmt":"2010-03-23T20:29:25","slug":"mdrna-down-to-1-7m-cash","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/463251","title":{"rendered":"MDRNA Down to $1.7M Cash"},"content":{"rendered":"\n
Biotech<\/a>, Finances<\/a>, RNA Interference<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

[Updated: 5:58 pm Pacific<\/em>] MDRNA (NASDAQ: MRNA<\/a>), the Bothell, WA-based developer of RNA interference drugs, said today<\/a> in its fourth quarter financial report that it had just $1.7 million of cash and investments left in the bank heading into 2010. That’s about half as much as the company had at the same time a year earlier. The company, which has no marketed products generating revenue, reported a net loss of about $800,000 in the fourth quarter of 2009.<\/p>\n

[Updated: 5:58 pm, with detail on January financing<\/em>] Even though MDRNA raised $7.5 million in a January financing, MDRNA said its auditing firm, KPMG, is likely to issue an opinion in the company’s annual report that raises doubt about its ability to continue as a “going concern.” MDRNA said it has enough cash to operate “well into the second quarter of 2010.”<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, Finances, RNA Interference Luke Timmerman wrote: [Updated: 5:58 pm Pacific] MDRNA (NASDAQ: MRNA), the Bothell, WA-based developer of RNA interference drugs, said today in its fourth quarter financial report that it had just $1.7 million of cash and investments left in the bank heading into 2010. That’s about half as much as the company […]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-463251","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/463251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=463251"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/463251\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=463251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=463251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=463251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}